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Abstract
Background
Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscu-
lar (i.m.) injection for 3 d would be simpler and more appropriate for remote health facilities
than the current WHO-recommended regimen of five intravenous (i.v.) or i.m. injections
over 4 d. We compared both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen
with the standard five-dose regimen using a non-inferiority design (with non-inferiority mar-
gins of 10%).
Methods and Findings
This randomized controlled trial included children (0.5–10 y) with severe malaria at seven
sites in five African countries to assess whether the efficacy of simplified three-dose regi-
mens is non-inferior to a five-dose regimen. We randomly allocated 1,047 children to
receive a total dose of 12 mg/kg ARS as either a control regimen of five i.m. injections of 2.4
mg/kg (at 0, 12, 24, 48, and 72 h) (n = 348) or three injections of 4 mg/kg (at 0, 24, and 48 h)
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either i.m. (n = 348) or i.v. (n = 351), both of which were the intervention arms. The primary
endpoint was the proportion of children with99% reduction in parasitemia at 24 h from
admission values, measured by microscopists who were blinded to the group allocations.
Primary analysis was performed on the per-protocol population, which was 96% of the
intention-to-treat population. Secondary analyses included an analysis of host and parasite
genotypes as risks for prolongation of parasite clearance kinetics, measured every 6 h, and
a Kaplan–Meier analysis to compare parasite clearance kinetics between treatment groups.
A post hoc analysis was performed for delayed anemia, defined as hemoglobin 7g/dl 7 d
or more after admission.
The per-protocol population was 1,002 children (five-dose i.m.: n = 331; three-dose i.m.:
n = 338; three-dose i.v.: n = 333); 139 participants were lost to follow-up. In the three-dose i.
m. arm, 265/338 (78%) children had a99% reduction in parasitemia at 24 h compared to
263/331 (79%) receiving the five-dose i.m. regimen, showing non-inferiority of the simplified
three-dose regimen to the conventional five-dose regimen (95% CI −7, 5; p = 0.02). In the
three-dose i.v. arm, 246/333 (74%) children had99% reduction in parasitemia at 24 h;
hence, non-inferiority of this regimen to the five-dose control regimen was not shown (95%
CI −12, 1; p = 0.24). Delayed parasite clearance was associated with the N86YPfmdr1 geno-
type. In a post hoc analysis, 192/885 (22%) children developed delayed anemia, an adverse
event associated with increased leukocyte counts. There was no observed difference in
delayed anemia between treatment arms.
A potential limitation of the study is its open-label design, although the primary outcome
measures were assessed in a blinded manner.
Conclusions
A simplified three-dose i.m. regimen for severe malaria in African children is non-inferior to
the more complex WHO-recommended regimen. Parenteral ARS is associated with a risk
of delayed anemia in African children.
Trial registration
Pan African Clinical Trials Registry PACTR201102000277177
Introduction
Studies to optimize artesunate (ARS) treatment regimens in malaria have been surprisingly
sparse, given that ARS is now established as the treatment of choice for severe malaria in both
adults and children [1,2]. WHO recommends ARS (2.4 mg/kg) administered by intravenous (i.
v.) or intramuscular (i.m.) routes at 0, 12, 24, 48, and 72 h after admission [2], although simpler
regimens would be preferable, assuming that safety and efficacy were not compromised [2].
The advantages of a simpler regimen are obvious to health care workers in under-resourced
settings, where finding and maintaining i.v. access in small, sick children to ensure that correct
doses are given on time is a challenge [1,3,4].
In an earlier study, a simplified three-dose ARS i.v. regimen was found to be non-inferior in
pharmacodynamic efficacy to the conventional WHO regimen [1], and its pharmacokinetics
(PK) were defined with a formulation that conformed to standards of good manufacturing
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practice. Since then, WHO has prequalified another formulation of ARS (Guilin Pharmaceuti-
cal, Shanghai, China), making it more widely used. We have also compared the i.v. and i.m.
routes of this product for severe malaria in African children and have described the PK of a
WHO-recommended dose regimen using ARS [4]. This regimen of one dose of 2.4 mg/kg fol-
lowed by four doses of 1.2 mg/kg has been superseded by a regimen of five doses of 2.4 mg/kg,
and there has since been debate about the simplified (once daily) i.v. regimen for severe malaria
[5,6]. The i.m. route has not yet been studied in adequately powered dose optimization trials.
We examined i.m. ARS in severe malaria in seven hospitals of the Severe Malaria in African
Children (SMAC) network [7,8]. We assessed whether splitting the total dose of 12 mg/kg into
a simplified once daily i.m. or i.v. three-dose regimen (4 mg/kg per dose) is non-inferior to the
WHO-recommended five-dose regimen (2.4 mg/kg per dose). We also examined associations
of genetic polymorphisms of pfmdr1 and kelch-13 with parasite clearance kinetics and, in post
hoc analysis, the occurrence of delayed anemia.
Our primary study objective was to assess the non-inferiority of i.v. ARS and i.m. ARS sim-
plified dosing regimens (4 mg/kg ARS at 0, 24, and 48 h; 12 mg/kg total dose) to the standard i.
m. treatment dosing regimen (2.4 mg/kg ARS at 0, 12, 24, 48, and 72 h; 12 mg/kg total dose) in
clearing parasitemia in African children with severe malaria. Our secondary study objectives
were to compare the tolerability and safety of the three ARS dosing regimens, to analyze host
and parasite genotypes as risks for prolongation of parasite clearance kinetics, measured every
6 h, and to compare parasite clearance kinetics between treatment groups. An exploratory
objective was to analyze genetic polymorphisms in humans and parasites linked to disease and
treatment, and a post hoc objective was to assess the occurrence of delayed anemia.
Methods
The trial was performed according to the principles of the Declaration of Helsinki and Good
Clinical Practice. Ethics committees and competent authorities for each study site approved
the study. A data monitoring board (DMB) provided oversight for the study with respect to
safety and efficacy as well as appropriate implementation of the defined stopping rules.
Study Design
This was an open-label, randomized, multicenter, parallel-group, three-arm study to compare
the antimalarial activity and safety of three ARS dosing regimens in children with severe Plas-
modium falciparummalaria. Patients (as shown in Fig 1) were randomly assigned to one of
three dosing regimens consisting of a total of 12 mg/kg parenteral ARS: (i) 2.4 mg/kg i.m. on
admission and at 12, 24, 48, and 72 h, (ii) 4 mg/kg i.m. on admission and at 24 and 48 h, and
(iii) 4 mg/kg i.v. on admission and at 24 and 48 h. Time points of administration of ARS for
each group are represented in Table 1.
Parasitemia was measured by thick blood smears at 6-h intervals and prior to the each dose
of treatment for at least 48 h following the first dose of study drug, or until three consecutive
negative smears were recorded within the last 24-h period. Thick blood films were also exam-
ined on days 7, 14, and 28.
The primary efficacy endpoint was the proportion of patients with99% parasite reduction
from the baseline asexual parasite count at 24 ± 1 h. Parasitemia was always quantitated before
the 24-h dose was administered, i.e., after either one (intervention arms) or two (control arm)
doses of ARS had been administered. This endpoint was derived from discussions in the
SMAC network and from our own studies [1,4] and is based on the following reasoning. First,
WHO guidelines for the treatment of severe malaria [9] are based on studies that have used
multiple outcomes. For efficacy, these are death, parasite clearance time, fever clearance time,
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time to discharge from hospital (days), and coma resolution time. As studies using mortality as
an endpoint are impracticable in seasoned centers where overall mortality from severe malaria
is<5%—requiring sample sizes that are too large—we have chosen a parasitemia clearance
parameter as an endpoint. Parasite clearance kinetics was also used when a quinine loading
dose (20 mg/kg salt, if no pretreatment) was being developed and compared with the then stan-
dard dose (10 mg/kg salt), when a mortality study comparing the two regimens was ruled out
on sample size grounds. Parasite clearance time was a crucial determinant of efficacy for com-
paring the same drug in two dosing regimens [10]. In severe malaria, clinically advantageous
benefits of more rapid clearance of parasites by ARS (even when given by suppository) have
been reported in comparison with i.m. artemether [11]. The 24-h time point was chosen as an
Fig 1. Trial profile. *These patients completed the study but were not included for the primary endpoint analysis because of protocol deviations. $These
patients completed the study but were not included for the primary endpoint analysis because of sampling issues. +These patients completed the study but
were not included for the primary endpoint analysis because of dosing issues. §Lost to follow-up includes patients who (i) withdrew consent (n = 8), (ii) moved
from the study area (n = 9), and (iii) were discharged from the study due to malaria infection on day 28 (n = 1), amongst a variety of other reasons.
doi:10.1371/journal.pmed.1001938.g001
Table 1. Dosing regimen of artesunate.
Group Route Dose 0 h 12 h 24 h 48 h 72 h
Five-dose i.m. i.m. 2.4 mg/kg X X X X X
Three-dose i.m. i.m. 4.0 mg/kg X X X
Three-dose i.v. i.v. 4.0 mg/kg X X X
doi:10.1371/journal.pmed.1001938.t001
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endpoint because most deaths (>60%) from severe malaria take place within 24 h of admission,
and accurate assessment of parasitemia becomes more difficult at later time points.
Evaluation of the whole regimens is included in the secondary outcome measures (and
there is no discrepancy between the results for this and the 24-h end point). Further endpoints
were time to total clearance of asexual parasites, time to 99% reduction of asexual parasites,
time to 90% reduction of asexual parasites, time to 50% reduction of asexual parasites, propor-
tion of patients with genotype-uncorrected adequate clinical and parasitological response on
day 28, percent reduction in asexual parasites from baseline at 24 h after initiation of random-
ized study drug, and percent reduction in asexual parasites from baseline at 48 h after initiation
of randomized study drug.
During the conduct of this study, several patients in the case series developed delayed hemo-
lytic anemia following ARS therapy, mostly in the second and third week from the start of ther-
apy [12–15]. Motivated by these events, we amended our trial protocol and undertook two
exploratory post hoc analyses of delayed anemia. In the first, all trial participants were screened
and treated for delayed anemia, defined as hemoglobin (Hb) 7 g/dl seven or more days after
admission. In the second, a subgroup of 72 patients in Kumasi and Lambaréné who underwent
detailed hematological monitoring for 28 d following discharge from the hospital were assessed
for hemoglobin and laboratory markers of hemolysis (such as lactate dehydrogenase) during
follow-up [16]. For the patients in the subgroup, we were able to assess laboratory markers of
hemolysis (such as lactate dehydrogenase) in more intensive follow-up, whereas the last day of
scheduled sampling for these particular markers for all other patients in the study was day 7.
Participants
Children were aged 6 mo to 10 y, with a diagnosis of P. falciparum infection (parasitemia
5,000 parasites/μl on initial blood smear) and clinical signs and symptoms severe enough to
require hospitalization, according to the SMAC definition of severe malaria that best reflects
the policies of African hospitals [7,8]. Most (87%) of these children also fulfilled one or more
criteria of the WHO definition of severe malaria [17], which include severe anemia (hematocrit
of<15% or Hb< 5 g/dl with a parasite density of>10,000/μl), hyperlactatemia (5 mmol/l),
hyperparasitemia (>250,000 parasites/μl), hypoglycemia (whole blood or plasma glucose
2.2 mmol/l), and hemoglobinuria (urine that is dark red or black, with a dipstick that is positive
for Hb/myoglobin).
In addition, children were required to be willing and able to comply with the study protocol
for the duration of the study, be willing to remain in the hospital for at least 3 d, and have had
written informed consent provided by their parents or guardians. Exclusion criteria included
known serious adverse reaction or hypersensitivity to artemisinins, any underlying disease that
might compromise the diagnosis and evaluation of the response to the study medication, par-
ticipation in any investigational drug study during the 30 d prior to screening, and adequate
(according to WHO and country-specific guidelines) antimalarial treatment within 24 h prior
to admission.
Patients were recruited at the Centre de Recherches Médicales de Lambaréné, Lambaréné,
Gabon (n = 245); Queen Elizabeth Central Hospital, Blantyre, Malawi (n = 211); the Université
des Sciences de la Santé, Libreville, Gabon (n = 150); the School of Medical Sciences at the Uni-
versity of Science and Technology (Komfo Anokye Teaching Hospital), Kumasi, Ghana (n =
149), Kenya Medical Research Institute Kondele Children’s Hospital, Kisumu, Kenya (n =
129); Edward Francis Small Teaching Hospital (former Royal Victoria Teaching Hospital),
Medical Research Council Laboratories, Banjul, The Gambia (n = 90); and the Kenya Medical
Research Institute Centre for Geographic Medicine–Coast, Kilifi, Kenya (n = 73).
Artesunate and Severe Malaria in Children
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A total of 45 participants were lost to follow-up between the time of randomization and the
primary endpoint analysis time point at 24 h. Loss to follow-up was due to death, withdrawal
of consent, protocol deviations, not receiving all doses, or sampling issues. Sampling issues
were defined as physical difficulties in obtaining blood due to the small size of participants and
difficulties with venipuncture. A total of 139 participants were lost to follow-up after the 24-h
primary endpoint analysis time point. Participants were considered lost to follow-up after the
24-h time point if they were unable to be reached when research staff tried to contact them at
least five times at two different times of day via telephone, and with at least two house visits,
within a 2-wk period.
Patient participation included hospitalization for at least 3 d and follow-up for at least 28 d
following the first dose of study drug. Participants had scheduled follow-up visits in the clinic
on days 7, 14, and 28, during which vital sign evaluation, physical examination, adverse event
(AE) review, and blood sampling for hematology, biochemistry, parasitological assessments,
PK analysis, and exploratory analyses were conducted
Randomization and Masking
Randomization was balanced at each study site in a 1:1:1 ratio for each regimen. Randomiza-
tion cards were supplied in numbered, sealed envelopes. The envelope for each participant was
opened after inclusion in the trial, directly before treatment initiation. Microscopists were not
informed about group allocations.
Procedures
ARS for injection (Artesun; Guilin Pharmaceutical, Shanghai, China) was supplied as powder
and reconstituted before injection. Artemether-lumefantrine was given at discharge in a weight-
normalized dosing regimen [18].
Other concomitant therapies were given according to published guidelines [2] and the stan-
dard operating procedures of the sites. Malarial infection recurring within 28 d was treated
with artemether-lumefantrine.
Malaria smears were done every 6 h until three consecutive negative smears were recorded
[19] and were read independently by two microscopists. Vital signs were recorded at least
twice daily, and physical examination was done repeatedly, over the period of hospitalization.
Population PK studies were performed on a subset (n = 288) of patients for the parent com-
pound ARS, the primary metabolite dihydroartemisinin (DHA) and the secondary metabolite,
the primary DHA glucuronide (DHAG), using established population PK techniques that were
refined using the results of the first dose optimization study [1]. PK data were available for 39
of the patients in the anemia analysis. Venous samples (400 μl) were collected 30, 60, 120, 240,
or 360 min after each of three dosings. Allocation to one of the five predefined sampling time
points was random within each treatment arm. Samples were stored at −80°C until use. ARS,
DHA, and DHAG concentrations were assayed using liquid chromatography/mass spectrome-
try [20]. In total, 851 samples were analyzed from three study centers (from 116 patients from
Lambaréné, 84 from Kisumu, and 88 from Kumasi). Parasite and host polymorphisms were
examined in the following genes using published methods and primers for PCR: pfmdr1, kelch-
13, the sickle cell gene, and the gene for glucose-6-phosphate dehydrogenase (G6PDH) [20,21].
This analysis was carried out on the subset of patients included in the PK analysis.
Statistical Analysis
Fisher’s exact test for one-sided equivalence [22] was used to assess treatment group differences
in parasite clearance for the per-protocol (PP) and intention-to-treat (ITT) populations, and
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PLOSMedicine | DOI:10.1371/journal.pmed.1001938 January 12, 2016 6 / 22
the 95% CI of the difference in proportion is given. Primary analysis was on the PP population,
since it is more conservative in non-inferiority models. Testing was done hierarchically, with
comparisons of the two experimental arms (three-dose i.m. and three-dose i.v.) against the
control (five-dose i.m.), corrected for multiple testing using the Bonferroni method. Only
when both tests rejected the null hypothesis was a further test comparing the two experimental
arms planned. As secondary endpoints, parasite clearance times were calculated using Kaplan–
Meier estimates and a Cox model with treatment arm and study center as covariates, when not
otherwise described. Alpha< 0.05 was considered significant.
The needed sample size was calculated based on the results of our prior study [1,6]. We
assumed that 82% of patients would have a99% reduction in parasitemia at 24 h (primary
endpoint) and set power to 0.8, alpha to 0.05, and delta to 0.1. Using the Farrington and Man-
ning procedure [23] as implemented in the Design package of R v. 2.10.1, the calculated sample
size needed was 316 per arm when multiple comparisons between the groups were included.
The total estimated sample size needed, with 10% headroom for loss to follow-up, was there-
fore 1,044 participants.
The non-inferiority margin delta was pre-specified as an absolute difference of 10% for the
primary endpoint on the basis of our previous study [1] and published methods for analyzing
time-to-event outcomes [24]. For the Cox model, the non-inferiority margin was translated
into a hazard ratio (HR) assuming a 82% cure rate (99% reduction in parasitemia at 24 h)
with the control (five-dose i.m.) regimen and an at least 72% cure rate with the experimental
(three-dose i.m. and three-dose i.v.) regimens.
All patients who received at least one dose of the study drug were included in the safety
analysis. Delayed anemia was analyzed using a logistic regression model for non-hematological
variables, a two-way ANOVA for genotype analysis, and an ANCOVA for hematological
variables.
Descriptive statistics for the drug concentration data were calculated for the set of all
patients in this study who received the full dose of ARS and who had plasma concentration
data available. A population PK model, assuming 100% conversion of ARS to DHA, was devel-
oped using the nonlinear mixed-effects modeling software Phoenix NLME 1.2 (Pharsight,
St. Louis, Missouri, US). The final population PK models for ARS, DHA, and DHAG were eval-
uated using visual predictive checks. Plasma concentration over time data were described by a
one-compartment PK model with additive residual error and an exponential term for interpati-
ent variability. Initial PK parameter estimates were from our previous SMAC trial [1]. Route of
administration, study center, weight, age, height, delayed anemia, parasitemia, and host and
parasite genotypes were added as covariates in the model by stepwise forward inclusion. Model
improvement by covariates was statistically tested by the decrease in −2 log likelihood. The
final population PK model included all covariates associated with a significant increase in log
likelihood (5% significance).
Role of the Funding Source
The clinical sponsor of the trial was Universitätsklinikum Tübingen, and the corresponding
author P. G. K. acted as the sponsor’s representative. The corresponding authors had full
access to all of the data in the study and had final responsibility for the decision to submit for
publication.
Results
In all, 1,047 patients were randomized and received at least one dose of study drug, as shown
in Fig 1. This is the safety population and also defines the ITT population as all patients had
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P. falciparum infection. The PP population is defined as all patients from the ITT population
who received all doses of randomized study drug and for whom the primary endpoint could be
calculated. This is the primary analysis population for efficacy and is 96% of the ITT popula-
tion (n = 1,002).
Recruitment was from 4 July 2011 until 25 September 2012. As pre-specified in the protocol,
after 50 patients completed the trial procedures up to 72 h, all serious AEs (SAEs) including
deaths were reviewed by the DMB, with no findings that required stopping the study. After 100
patients completed the trial up to 24 h in each cohort, parasitemia evaluations were reviewed
by the DMB to confirm that in all cohorts, 99% reduction in parasitemia was achieved in at
least 60% of patients after 24 ± 1 h (stopping rule). After DMB reviews, there was no finding
to stop recruitment. There were to be ad hoc reviews if SAEs and/or deaths in one cohort
increased significantly compared with any other. For deaths in any cohort, the threshold to
trigger review by the DMB was 4% (stopping rule), but it was not invoked. Anemia was studied
in patients as shown in Fig 2. Table 2 summarizes the baseline demographic, clinical, and labo-
ratory variables of patients in the ITT population.
Figs 3 and 4 present evidence that the three-dose i.m. route for ARS is non-inferior to the
WHO-recommended five-dose i.m. regimen. Both i.m. routes had a higher proportion of
patients with99% reduction in parasitemia at 24 h (78%, or 265/338, for the three-dose i.m.
group and 79%, or 263/331, for the five-dose i.m. group) (by about 5%) than the three-dose i.v.
route (74%, or 246/333). This three-dose i.v. regimen had previously been found to be compa-
rable in efficacy to the WHO-recommended five-dose i.v. regimen [1]. Time to 99% parasite
clearance, specified as a secondary analysis, was comparable between treatment groups (Fig 5;
S1 Table). Since the Fisher’s exact test for one-sided equivalence does not account for stratify-
ing covariates, which may be anti-conservative, the robustness of the results was tested with
Cox proportional hazards models adjusted for study center, which showed non-inferiority
(lower confidence interval limit of the HR> 0.74) [24,25] for all comparisons (three-dose i.m.
versus five-dose i.m., HR 1.04 [97.5% CI 0.88–1.24]; three-dose i.v. versus five-dose i.m., HR
0.89 [97.5% CI 0.75–1.06]; three-dose i.m. versus three-dose i.v., HR 1.18 [95% CI 1.00–1.37]).
For the three treatment groups, the estimates of time to 90% parasite clearance, adjusted for
center and initial parasitemia, were significantly different (Fig 6). This difference can be attrib-
uted to a more rapid clearance in the three-dose i.m. group compared with the five-dose i.m.
group (HR 1.21 [95% CI 1.04–1.41]). In addition, no difference was seen in fever clearance
time between groups (S3–S5 Tables). No case required rescue treatment before discharge from
hospital, and 16 patients died, with no group differences. There were 41/885 (5%) patients who
were parasitemic at 28 d: 13 in the three-dose i.v. group, 11 in the three-dose i.m. group, and 17
in the five-dose i.m. group.
N86YPfmdr1 was found in 107/287 (37%) parasites and was associated with delayed time to
99% and 100% parasite clearance estimates of 2.8 h (95% CI 0.9–4.8 h; p = 0.005) and 4.8 h
(95% CI 1.9–7.6 h; p< 0.001), respectively. No other N86YPfmdr1 polymorphisms (Y184F,
S1034C, N1042D, and D1246Y), including increased gene copy number of pfmdr1 (found in
13 samples, 5%), were associated with time to parasite clearance. There were no previously
reported polymorphisms in kelch-13 sequences (M476I, Y493H, R539T, I543T, and C580Y).
Tests of associations between parasite genotypes and clearance time estimates were corrected
for center and treatment group.
Drug detection was linear, with ranges of 1–2,500 nM, 165–16,500 nM, and 4–10,000 nM
for ARS, DHA, and DHAG, respectively. In total, 851 samples from 288 patients (153 male and
135 female, aged 0.5 to 10 y, mean 3.8 y) were analyzed: 92, 99, and 97 patients received the
five-dose i.m., three-dose i.m., and three-dose i.v. regimens, respectively. The population esti-
mates of PK parameters of the base models are presented in Table 3. These data confirm that
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the three regimens studied are comparable in their PK parameters, with the exception of a
larger volume of distribution of DHA following i.m. injection. In particular, estimates of time
to clearance were comparable between groups. Fig 7 presents plots of observed concentration–
time profiles for ARS, DHA, and DHAG according to treatment regimen. Estimated popula-
tion mean PK profiles are shown by the red lines. Interestingly, ARS plasma concentrations
varied more after i.v. than after i.m. administration. Study center, age, sex, weight, parasitemia,
and delayed anemia were considered as covariates. Of these covariates, parasitemia influenced
volume of distribution after i.v. ARS only, while the strongest influence was seen for study cen-
ter on volume of distribution/bioavailability and clearance of ARS (i.m.), DHA, and DHAG.
The occurrence of laboratory and clinical AEs and SAEs (Table 4) was similar in the three
groups. Out of 75 SAEs, 14 (five severe anemia, six persistent fever, two vomiting, and one
cough) were judged as possibly related to the study drug.
Fig 2. Post hoc analyses of patients with anemia. The right hand side of the diagram (in red) shows patients included in the substudy.
doi:10.1371/journal.pmed.1001938.g002
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During the conduct of this trial, a series of case reports described delayed hemolytic anemia
in travelers after receiving artemisinins [26] and prompted an urgent evaluation of the risk of
delayed hemolysis in a subset of our patients in Kumasi and Lambaréné, in whom detailed
hematological monitoring after discharge was possible, as an amendment to the protocol [16].
For these patients, we defined delayed hemolysis as the coexistence of (i) low haptoglobin
(<0.30 mg/dl) on day 14, (ii) any decrease in hemoglobin between days 7 and 14, and (iii) any
increase in lactate dehydrogenase between days 7 and 14 leading to a lactate dehydrogenase
level of over 350 U/l on day 14.
This substudy identified five out of 72 evaluable patients with anemia between days 7 and
28 [16]. In a post hoc analysis, we also included anemia detected by hemoglobin measurement
Table 2. Patient clinical and laboratory findings on admission in intention-to-treat population.
Variable Arm Total (n = 1,047)
Three-Dose i.v. (n = 351) Three-Dose i.m. (n = 348) Five-Dose i.m. (n = 348)
Clinical ﬁndings
Female 162 (46%) 166 (48%) 168 (48%) 496 (47%)
Male 189 (54%) 182 (52%) 180 (52%) 551 (53%)
Age, y 4.0 (2.4) 4.1 (2.5) 4.2 (2.5) 4.1 (2.5)
Aged 0–3 y 201 (57%) 185 (53%) 185 (53%) 571 (54%)
Aged 4–7 y 122 (35%) 132 (38%) 130 (37%) 384 (37%)
Aged >8 y 28 (8%) 31 (9%) 33 (10%) 92 (9%)
Pulse, beats/minute 134 (26) 133 (25) 133 (25) 133 (25)
Respirations/minute 40 (13) 39 (11) 40 (13) 40 (12)
Temperature, °C 38.2 (1.2) 38.1 (1.2) 38.1 (1.2) 38.1 (1.2)
Weight, kg 14.3 (5.3) 14.3 (5.0) 14.8 (5.1) 14.4 (5.5)
Laboratory ﬁndings
Parasitemia per microliter × 10−3* 129.0 (4.6–2,965.0) 114.0 (5.0–1,439.0) 119.0 (4.1–2,675.0) 121.0 (4.1–2,965.0)
Hb, g/dl 8.5 (2.4) 8.7 (2.3) 8.7 (2.4) 8.6 (2.4)
White blood cell count, 103/μl 10.3 (5.5) 10.1 (5.2) 9.7 (4.6) 10.0 (5.1)
Neutrophils, 103/μl 5.5 (3.2) 5.3 (3.0) 5.4 (3.3) 5.4 (3.2)
Platelet count, 103/mm3 115 (117) 107 (108) 123 (130) 115 (119)
Clinical signs of severe malaria
Severe anemia 34 (10%) 42 (12%) 40 (11%) 116 (11%)
Hyperlactatemia 21 (6%) 18 (5%) 23 (7%) 62 (6%)
Hyperparasitemia 103 (29%) 91 (26%) 103 (30%) 297 (28%)
Hypoglycemia 13 (4%) 7 (2%) 18 (5%) 38 (4%)
Jaundice 28 (8%) 29 (8%) 25 (7%) 82 (8%)
Hemoglobinuria 6 (2%) 6 (2%) 7 (2%) 19 (2%)
Respiratory distress 30 (9%) 35 (10%) 28 (8%) 93 (9%)
Severe vomiting 25 (7%) 36 (10%) 26 (7%) 87 (8%)
Prostration 169 (48%) 160 (46%) 140 (40%) 469 (45%)
Cerebral malaria 32 (9%) 28 (8%) 23 (7%) 83 (8%)
Generalized seizures 39 (11%) 44 (13%) 28 (8%) 111 (11%)
Data are given as mean (standard deviation) or n (percent), except for parasitemia per milliliter, which is given as geometric mean (range). Clinical
classiﬁcation was according to the following deﬁnitions: severe anemia (hematocrit of <15% or Hb < 5 g/dl with a parasite density of >10,000/μl),
hyperlactatemia (5 mmol/l), hyperparasitemia (>250,000 parasites/μl), hypoglycemia (whole blood or plasma glucose  2.2 mmol/l), and hemoglobinuria
(urine that is dark red or black, with a dipstick that is positive for Hb/myoglobin).
*PP population.
doi:10.1371/journal.pmed.1001938.t002
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on day 7 or later. This increased the total number of patients with anemia (Hb 7 g/dl) a week
or more after the start of therapy to 192, although most were detected on day 7 due to sampling
bias, as the last scheduled blood sampling per protocol in our study was day 7. We also investi-
gated the AEs in all our patients (including those reported earlier [16]) by assessing anemia
at passive follow-up after day 7, and detailed information is given in Table 5. This analysis
includes the 72 patients from our earlier reported substudy [16].
We examined the relationships between other hematological variables, parasitemia, and
delayed anemia, and allowed for admission values by including these in covariance analysis of
the full dataset. There was no significant association between delayed anemia and admission
parasitemia (p = 0.30) or platelet counts on day 7 (p = 0.11). A significant association emerged
with leukocyte count (p< 0.001) and neutrophil count (p< 0.001) on day 7. Those with
delayed anemia had higher leukocyte (Fig 8) and neutrophil counts than those without delayed
anemia, regardless of the definition applied for delayed anemia.
G6PDH-deficient participants (A−) had more anemia on admission (odds ratio 4.3 [95% CI
2.1–9.0], p< 0.001) than those with G6PDH non-deficient genotypes, but this relationship did
not hold for delayed anemia (odds ratio 1.4 [95% CI 0.6–3.2]). HbAC or HbAS genotype was
not associated with delayed anemia, and there was no relationship between delayed anemia
and PK parameters.
Discussion
This study consolidates previous work aiming to optimize dosage regimens using parenteral
ARS for severe malaria [1]. Here, simpler three-dose i.m. and i.v. regimens have been compared
Fig 3. Per-protocol population primary endpoint analysis. PP treatment difference in proportions of
patients with99% parasite reduction, with corresponding 95% confidence intervals. The vertical line
indicates the non-inferiority margin (δ). The three-dose i.m. treatment group is non-inferior to the five-dose i.
m. treatment group (p = 0.02), whereas the three-dose i.v. group is not non-inferior (p = 0.24). Note that the p-
value is calculated using Fisher’s exact test for one-sided equivalence under the assumption that both
regimens are equally efficacious.
doi:10.1371/journal.pmed.1001938.g003
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to the WHO-recommended five-dose i.m. regimen. This study provides new insights into ARS
PK, delayed anemia, and genetic markers of delayed parasite clearance. Our studies used the
pharmacodynamic endpoint of parasite clearance rather than other clinical outcome measures
such as mortality because the latter requires impracticably large studies (as debated [5,6]). In
comparing the same drug given in different doses and by different routes, parasite clearance
kinetics should accurately reflect differences in in vivo antiparasitic activity because the
mechanism of action is the same. It follows that if there are no differences in parasite clearance
kinetics between treatments, then they can be considered to be of comparable efficacy. For
uncomplicated malaria, for example, inadequate oral dosing with ARS is associated with pro-
longed parasite clearance kinetics, and in severe malaria a loading dose of quinine significantly
shortened parasite clearance times compared with a non-loading-dose regimen [10,26].
From our previous study, we concluded that a simplified once daily regimen was non-infe-
rior in efficacy to the conventional i.v. ARS dosing regimen [1]. This study establishes that the
once daily i.v. is not consistently non-inferior to the three-dose and five-dose i.m. regimens.
There are several corollaries to this observation. First, clearance kinetics with i.v. once daily
ARS in this study (74% achieved99% clearance from baseline at 24 h) is very similar to the
previous result of 76% with i.v. once daily ARS. This latter result was also comparable to the
five-dose WHO-recommended i.v. regimen in that smaller study and points to a preference for
the i.m. route because it is associated with faster clearance kinetics (Figs 5–7). Second, these
results confirm that the endpoint chosen is both robust and pharmacodynamically sensitive as
a measure of ARS antimalarial efficacy. Also, a once daily simplified i.m. regimen is of compa-
rable efficacy to the five-dose WHO-recommended i.m. regimen, a finding that was robust
Fig 4. Intention-to-treat population primary endpoint analysis. ITT treatment difference in proportions of
patients with99% parasite reduction, with corresponding 95% confidence intervals. The vertical line
indicates the non-inferiority margin (δ). The three-dose i.m. treatment group is non-inferior to the five-dose i.
m. treatment group (p = 0.02), whereas the three-dose i.v. group is not non-inferior (p = 0.24). Note that the p-
value is calculated using Fisher’s exact test for one-sided equivalence under the assumption that both
regimens are equally efficacious.
doi:10.1371/journal.pmed.1001938.g004
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when analyzed using different statistical methodologies. This finding has important implica-
tions for practice. The i.m. route for administration of antimalarials is preferable to the i.v.
route in small children [27]. Analysis of secondary endpoints of parasite clearance supports the
results of the primary endpoint analysis, and suggests that the once daily i.m. regimen has an
even faster time to 90% parasite clearance than the conventional i.m. regimen (median 12 ver-
sus 18 h; Figs 5 and 6; S1 Table).
The frequently observed N86YPfmdr1 polymorphism has previously been associated with
increased sensitivity to artemisinin in in vitro assays in Senegal [28] and decreased sensitivity
to artemether in Nigeria [29], with no effect in Thai isolates [30]. Our results provide in vivo
evidence for decreased sensitivity to ARS (DHA) of parasites with N86YPfmdr1. Changes in the
frequencies of polymorphisms in pfmdr1 are clearly worth monitoring in future epidemiologi-
cal studies. High unadjusted cure rates (95%) in our patients may reflect the large artemisinin
(24 mg/kg total dose of ARS and artemether) component of the treatment course and efficacy
of the combination partner (lumefantrine).
Fig 5. Kaplan–Meier plot for time to 99% parasite clearance in the per-protocol population. Time to 99% parasite clearance under parenteral ARS
treatment is shown. Using the 10% delta at 24 h, both three-dose regimens are non-inferior to the five-dose regimen in a Cox proportional hazards model.
The PP population has been used for the secondary endpoints.
doi:10.1371/journal.pmed.1001938.g005
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The results of our population PK analysis are consistent with classical and previous popula-
tion PK studies on parenteral ARS [4,6], including in Tanzania [31]. A suggestion, based on
modeling, that doses higher (~3 mg/kg per dose for children<10 kg) [31] than currently rec-
ommended by WHOmay be needed for smaller children is obviated if our higher dose (4 mg/
kg) and simpler regimen is implemented. As noted previously, there was no relationship
Fig 6. Kaplan–Meier plot for time to 90% parasite clearance in the per-protocol population. Time to 90% parasite clearance under parenteral ARS
treatment is shown. Using the 10% delta at 24 h, both three-dose regimens are non-inferior to the five-dose regimen in a Cox proportional hazards model.
The PP population has been used for the secondary endpoints.
doi:10.1371/journal.pmed.1001938.g006
Table 3. Population pharmacokinetic analysis of parenteral artesunate in severemalaria.
Arm Drug Metabolite Volume of Distribution (Liters) (95% CI) Clearance (Liters/Hour) (95% CI)
Three-dose i.v. ARS 32.0 (22.3–41.6) 42.0 (28.9–55.1)
DHA 12.0 (10.2–13.8) 9.9 (8.4–11.3)
DHAG 36.6 (32.0–41.3) 10.8 (9.0–12.7)
Three-dose or ﬁve-dose i.m ARS 21.1 (18.2–24.0) 33.3 (29.5–37.1)
DHA 25.3 (22.4–28.2) 8.5 (7.4–9.5)
DHAG 66.5 (58.2–74.8) 10.1 (8.3–11.9)
doi:10.1371/journal.pmed.1001938.t003
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between PK parameters and efficacy. We also present, to our knowledge for the first time, an
analysis of the glucuronide derivative of DHA (Fig 7; Table 3). This is quantitatively the most
important primary metabolite of DHA. Although it has poor antimalarial activity (IC50 of
DHAG = 5.7 μM, mean of two experiments), DHAG plasma concentrations commonly peaked
above 5 μM (Fig 7), rendering a contribution to parasite clearance possible. Repeated dosing
with ARS, in any regimen, does not show evidence of accumulation (Fig 7). This analysis also
allows us to examine other potential mechanisms for toxicity, which hitherto has not been
possible.
During the conduct of our trial a series of case reports appeared about delayed anemia in
travelers who had received parenteral ARS. Therefore, we amended the study protocol to address
Fig 7. Population pharmacokinetic profiles of artesunate, dihydroartemisinin, and dihydroartemisinin glucuronide. Plots of observed concentration–
time profiles for ARS and its major metabolites, DHA and DHAG, are presented according to treatment regimen. Estimated population mean PK profiles are
shown by red lines. The three columns of results for each regimen represent the findings after each dose.
doi:10.1371/journal.pmed.1001938.g007
Table 4. Serious adverse events in the intention-to-treat population.
SAE Outcome Arm Total
Three-Dose i.v. Three-Dose i.m. Five-Dose i.m.
SAEs 26 28 21 75
SAEs with a possible relationship to study drug 5 (19%) 3 (11%) 6 (29%) 14
SAEs with no relationship to study drug 21 (81%) 25 (89%) 15 (71%) 51
Deaths 6 6 4 16
Neurological sequelae after study completion (day 28) 3 1 4
Data are given as n or n (percent).
doi:10.1371/journal.pmed.1001938.t004
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the occurrence of delayed hemolytic anemia in our ongoing study. We identified delayed anemia
after ARS treatment using a small subgroup of patients from the current study [16] in whom it
was possible to study anemia defined by several criteria (low haptoglobin, elevated lactate dehy-
drogenase level, decrease inHb, exclusion of sickle cell disease and G6PDH deficiency). Secondly,
in a post hoc analysis that included the whole study population, we defined delayed anemia as
Hb 7 g/dl 7 d or more after admission. We confirmed the occurrence of delayed anemia in a
significant proportion (22%) of African children by using this simplified definition that may
therefore have greater practical utility. This definition of anemia does not reveal any
Table 5. Anemia occurrences from day 7 until day 28.
Anemia Outcome Number of Patients
Total patients with at least one late anemia episode 192 out of 885 followed up until day 28
Hb  7 g/dl on day 7 185 out of 972 followed up until day 7
Hb  7 g/dl on day 28 7
Late transfusion (> day 7) 4
Anemia on active follow-up (substudy) 5
doi:10.1371/journal.pmed.1001938.t005
Fig 8. Association between delayed anemia and increased white blood cell count at day 7. Individual
white cell counts (WBC) on day 7 (D7) are presented as medians and interquartile ranges, divided into those
who developed delayed anemia (12.8 × 103/μl, interquartile range 9.6–17, n = 186) and those who did not
(10.1 × 103/μl, interquartile range 8.1–12.4, n = 689). Patients with delayed anemia had a significantly higher
white blood cell count at day 7 (p < 0.001).
doi:10.1371/journal.pmed.1001938.g008
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relationships with PK parameters for ARS, DHA, or indeed DHAG. Instead, a higher leucocyte
(Fig 8) and neutrophil count at day 7 is associated with delayed anemia, suggesting that if ARS is
the cause of anemia, the mechanism does not involve bone marrow toxicity, because ARS can
cause dose-dependent neutropenia [25]. In a recent study of 60 travelers treated with ARS for
severe malaria, 13/66 (22%) had delayed anemia, which compares well with our findings. In this
study, pitting was significantly associated with delayed anemia [32]. Pitting is a process whereby
dead early-stage parasites are removed from erythrocytes by the spleen. Pitting may contribute
to the pathophysiology of delayed anemia, which is associated with markers of delayed hemoly-
sis, although available findings from AQUAMAT do not support this [33]. In the AQUAMAT
study, the incidence of post-admission severe anemia (Hb< 50 g/l) was comparable in the qui-
nine (5.7%) and ARS (4.6%) groups [34], and both groups had identical proportions of patients
(55%) receiving blood transfusions. It is unfortunate that only neurological sequelae were moni-
tored after discharge in the AQUAMAT study, as the risks of delayed anemia with ARS com-
pared to quinine could have been quantified in this cohort.
Weaknesses of this study are its open-label design, which may introduce biases in outcome
variables, although allocation bias was minimized and the primary outcome measures of para-
site clearance were assessed in a blinded way. The primary analysis at 24 h was before the full
treatment regimens had been completed, which may appear as a study limitation unless all par-
asite clearance estimates are also considered. Additionally, delayed anemia was first described
in travelers—and could therefore be addressed—only after the study was mostly complete. It
was studied in detail in 72 patients [16], with the remaining analysis being performed post hoc.
As there was no comparator arm using a drug other than ARS, further studies will be needed to
clarify the impact of artemisinins on delayed anemia. Some colleagues outside the SMAC net-
work may argue that mortality needs to be an endpoint in a study with severe malaria. How-
ever, our studies show that case fatality rates in severe malaria trials performed following
principles of good clinical practice should not exceed 5%, but rather be between 1% and 2%,
regardless of whether the WHO definition or our SMAC definition of cases is used [35]. Thus,
death as an endpoint is precluded by sample size requirements.
Simplifying ARS usage with a once daily i.m. regimen in severe malaria is supported by
our results, but because delayed anemia is common, patients should be monitored for this
complication.
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Editors' Summary
Background
Globally, about 200 million cases of malaria—a mosquito-borne parasitic disease—occur
every year. Malaria infections, which can be caused by several parasites, can be “uncompli-
cated” or “severe.” Prompt treatment of uncomplicated malaria, which presents with flu-like
symptoms, is essential to prevent the development of severe malaria. TheWorld Health
Organization (WHO) recommends artemisinin combination therapy (ACT) for the first-
line treatment of uncomplicated malaria in countries where the disease is always present. In
ACT, artemisinin derivatives (fast-acting antimalarial drugs that are cleared rapidly from
the body) are combined with a slower-acting, more slowly eliminated partner drug to pre-
vent the original infection recurring and to reduce the risk of the malaria parasites becoming
resistant to either drug. Severe malaria, which is usually caused by Plasmodium falciparum,
is characterized by anemia and by damage to the brain and other organs. Severe malaria kills
more than 400,000 people (mainly young children living in sub-Saharan Africa) every year.
WhyWas This Study Done?
WHO recommends that severe malaria be treated with intravenous or intramuscular injec-
tions of artesunate, a parenteral (injectable) form of artemisinin; patients with severe
malaria cannot take pills reliably or safely. Specifically, WHO recommends that patients be
given 2.4 mg of artesunate per kilogram of body weight intravenously or intramuscularly at
the time of admission (0 hours) and at 12, 24, 48, and 72 hours (followed by ACT to ensure
full parasite clearance). But this five-dose regimen is complex. A simpler regimen would be
easier to administer in resource-limited settings, where giving the correct doses on time to
small, sick children can be challenging. In this open-label, non-inferiority randomized con-
trolled trial (RCT), the researchers investigate the efficacy of a three-dose artesunate regi-
men for the treatment of severe malaria in African children. RCTs compare outcomes in
people randomly chosen to receive different interventions; in an open-label RCT, both the
researchers and the participants know which treatment is being given; a non-inferiority
trial investigates whether one treatment is not worse than another treatment.
What Did the Researchers Do and Find?
The researchers randomly allocated 1,047 children aged six months to ten years with severe
malaria attending seven clinical centers in five African countries to receive a total dose of
12 mg of artesunate per kilogram of body weight as five intramuscular injections of 2.4 mg/
kg given at 0, 12, 24, 48, and 72 hours (the control regimen) or as three intramuscular or
intravenous injections of 4 mg/kg given at 0, 12, and 24 hours (three-dose intramuscular
and intravenous regimens, respectively). The trial’s primary endpoint was the proportion
of children whose parasitemia (parasite count in the blood) at 24 hours was1% of that at
admission (in other words,99% parasite clearance). Among the 1,002 children who
received the planned drug doses (the per-protocol population), 78% in the three-dose intra-
muscular group had99% parasite clearance compared to 79% in the five-dose intramus-
cular group, a result that met a preset criterion for non-inferiority at 24 hours of the three-
dose intramuscular regimen to the control regimen. However, because only 74% of the chil-
dren in the three-dose intravenous group had99% parasite clearance, this regimen was
not shown to be non-inferior to the conventional five-dose regimen.
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What Do These Findings Mean?
These findings when combined with the findings of several secondary analyses suggest
that, in African children, a three-dose intramuscular artesunate regimen is non-inferior to
the WHO-recommended regimen for the treatment of severe malaria. The study’s open-
label design may limit the accuracy of its findings, as may its use of a primary endpoint
midway through drug treatment rather than at the end (the researchers note that 60% of
deaths from severe malaria occur during the first 24 hours of illness and that parasitemia
is harder to measure later during treatment) and its use of parasite clearance rather than
death as the primary endpoint (case fatality rates in severe malaria treatment trials are
very low, so a much larger study would be needed if death were used as the primary end-
point). Overall, these findings support the use of the three-dose intramuscular artesunate
regimen for the treatment of severe malaria. Importantly, however, 22% of the children in
the study developed delayed anemia, irrespective of treatment regimen. Thus, although
further studies are needed to clarify whether treatment with artesunate or the malaria
infection itself was responsible for the delayed anemia, patients treated with artesunate for
severe malaria should be routinely monitored for this complication.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001938.
• Information is available from the World Health Organization on malaria (in several lan-
guages); theWorld Malaria Report 2014 provides details of the current global malaria
situation, including information on malaria in individual African countries; WHO’s
Guidelines for the Treatment of Malaria and itsManagement of Severe Malaria: A
Practical Handbook are available
• The US Centers for Disease Control and Prevention provides information on malaria
(in English and Spanish), including personal stories about malaria
• The UK National Health Service Choices website also provides information about
malaria, including a personal story
• Information is available from the Roll Back Malaria Partnership on the global control of
malaria
• The Scientists Against Malaria collaboration applies modern drug design and modeling
techniques to develop new treatments against malaria; its website includes information
about many aspects of malaria
• Public Health England provides a collection of guidance and research and analysis on
malaria
• MedlinePlus provides links to additional information on malaria (in English and
Spanish)
• More information about this trial is available
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